Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a choline-containing compound that serves as a precursor to acetylcholine, a neurotransmitter critical for memory and cognitive function. With 41% choline content by weight and the ability to cross the blood-brain barrier, it is used to support cognitive function, memory enhancement, and neuroprotection in conditions ranging from mild cognitive impairment to Alzheimer's disease. It is available as both a prescription medicine and dietary supplement, depending on the country.

Overview

Alpha-glycerophosphocholine (Alpha-GPC, or L-alpha-glycerylphosphorylcholine) is a naturally occurring choline compound found in the brain and in various food sources including organ meats, wheat germ, and dairy products. It is formed endogenously during the metabolic breakdown of phosphatidylcholine by phospholipase enzymes and can also be manufactured commercially through enzymatic hydrolysis of soy lecithin. Alpha-GPC is considered one of the most bioavailable forms of supplemental choline, efficiently crossing the blood-brain barrier to support acetylcholine synthesis.

Clinical research on Alpha-GPC has primarily focused on cognitive function and neurodegenerative disease. In Europe, it has been investigated as an adjunctive treatment for Alzheimer's disease and vascular dementia, with several trials reporting improvements in cognitive scores (ADAS-cog, MMSE) over 3-6 month treatment periods at doses of 1,200 mg/day. A large Italian multicenter trial (the ASCOMALVA study) found that combining Alpha-GPC with donepezil produced superior cognitive outcomes compared to donepezil alone. Beyond dementia, Alpha-GPC has attracted interest in sports nutrition, with some studies suggesting it can acutely increase growth hormone secretion and enhance power output.

Alpha-GPC is available as a dietary supplement in the United States and as a prescription medication (Gliatilin, Delecit) in some European countries, typically dosed at 300-1,200 mg daily. It is generally well tolerated; the most commonly reported side effects include headache, heartburn, insomnia, and dizziness. A 2021 retrospective cohort study raised attention by associating long-term Alpha-GPC use with a modestly increased risk of stroke, though the study had significant limitations and causality has not been established.

Mechanism of Action

Cholinergic Pathway Enhancement

Alpha-glycerophosphocholine (alpha-GPC) is a phospholipid-derived choline compound that readily crosses the blood-brain barrier due to its amphiphilic structure. Once in the CNS, it is metabolized to free choline and glycerophosphate. The liberated choline serves as the immediate precursor for acetylcholine (ACh) synthesis via choline acetyltransferase (ChAT) in cholinergic neurons, directly increasing ACh availability in the hippocampus and cortex (PMID: 11589921).

Phospholipid Biosynthesis

The glycerophosphate moiety feeds into the Kennedy pathway for phosphatidylcholine (PC) synthesis, the most abundant phospholipid in neuronal membranes. This dual action — providing both choline for neurotransmission and substrate for membrane repair — distinguishes alpha-GPC from other choline donors like choline bitartrate or CDP-choline (PMID: 17562506).

Somatotropic Axis Modulation

Alpha-GPC stimulates growth hormone (GH) release through cholinergic activation of hypothalamic pathways. Acetylcholine inhibits somatostatin release from the periventricular nucleus while potentiating GHRH secretion, leading to increased pituitary GH output. Acute oral administration of 600 mg alpha-GPC has been shown to increase peak GH secretion during exercise (PMID: 22673596).

Neuroprotective Mechanisms

Alpha-GPC supports neuronal resilience through multiple downstream effects: stabilization of membrane fluidity, enhancement of nerve growth factor (NGF) receptor expression, and attenuation of age-related cholinergic neuron loss. In ischemic models, it reduces apoptotic signaling by preserving mitochondrial membrane potential and suppressing caspase-3 activation (PMID: 24835573).

Cognitive & Motor Output

By increasing both cortical and subcortical cholinergic tone, alpha-GPC enhances synaptic plasticity (long-term potentiation), attention, and memory encoding — while its effects on the neuromuscular junction support power output and reaction time.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Alpha-GPC (L-Alpha Glycerylphosphorylcholine)

Common Side Effects

• GI effects: Heartburn, nausea, diarrhea, abdominal pain (dose-dependent)
• CNS effects: Headache, dizziness, insomnia (particularly with evening dosing)
• Other: Fishy body odor (due to trimethylamine metabolite), skin rash (uncommon)

Serious Adverse Effects

• A 2021 observational study (Lee & Bhatt, JAMA Internal Medicine) raised concern about an association between long-term alpha-GPC use and increased stroke risk, particularly in patients >60 years — causality not established but warrants caution
• Rare reports of hypotension

Contraindications

• Known hypersensitivity to alpha-GPC or choline-containing compounds
• Caution in patients with history of stroke or TIA (based on observational data)
• Caution in patients with trimethylaminuria (fish odor syndrome)

Drug Interactions

• Anticholinergics: Alpha-GPC increases acetylcholine availability, potentially opposing anticholinergic drugs (e.g., scopolamine, diphenhydramine, oxybutynin)
• Cholinesterase inhibitors: Additive cholinergic effects when combined with donepezil, rivastigmine, or galantamine — monitor for cholinergic excess (bradycardia, excessive salivation, GI distress)
• Cholinergic agonists: Risk of cholinergic toxicity with concurrent use (e.g., bethanechol, pilocarpine)
• Anticoagulants: Choline may modestly affect platelet aggregation; monitor INR with warfarin

Special Populations

• Pregnancy/Lactation: Choline is an essential nutrient during pregnancy, but alpha-GPC supplementation specifically lacks safety data; prefer dietary choline sources
• Pediatric: Limited safety data; not recommended without medical supervision
• Elderly: Primary study population for cognitive benefits; start with lower doses; monitor cardiovascular status given stroke association data
• Hepatic impairment: Choline metabolism is hepatic; use with caution in severe liver disease

Monitoring Recommendations

• Blood pressure and heart rate, especially in elderly patients
• Monitor for cholinergic symptoms (excessive sweating, salivation, bradycardia)
• Lipid panel and cardiovascular risk assessment with long-term use
• Hepatic function in patients with pre-existing liver conditions

Regulatory Note: Alpha-GPC is a dietary supplement in the US and a prescription drug (Choline alfoscerate) in some European countries for cognitive disorders.

Pharmacokinetic Profile